Treatment of CLL with Autoimmune Haemolytic Anaemia or Immune Thrombocytopenia

Autoimmune cytopenias — specifically autoimmune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP) — occur in a meaningful proportion of patients with chronic lymphocytic leukaemia (CLL) and require a targeted management approach distinct from CLL-directed therapy alone.

Clinical Scenario

Autoimmune Complication

This protocol addresses CLL patients who develop autoimmune haemolytic anaemia (AIHA) or immune thrombocytopenia (ITP) as a complication of their disease. AIHA and ITP are relatively frequent in CLL (5%–7%) and should be managed in the same way as primary AIHA or ITP.

Treatment Approach

Management depends on the autoantibody subtype. In warm autoantibody-mediated cases, an immunosuppressive approach forms the backbone of first-line treatment. Cold AIHA follows a different pathway, particularly in transfusion-dependent patients who have not responded to non-pharmacological measures.

The full structured regimen — including agent selection, sequencing, and clinical decision points — is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Autoimmune haemolytic anaemia (AIHA) and, to a lesser extent, immune thrombocytopenia (ITP), are relatively frequent in CLL (5%–7%).
CLL patients with simple AIC should be managed in the same way as patients with primary AIHA or ITP (GRADE 1D).
Most patients with AIC, specifically those with warm auto-antibodies, respond to high-dose corticosteroids.
Patients with cold AIHA respond poorly to steroids, so the first-line choice is rituximab in transfusion-dependent cases who fail thermal protection measures.

View source ↗